PROCEPT BioRobotics Cash Flow Statement
NASDAQ: PRCTHealth CareMedical/Dental InstrumentsUSD
18.40+0.50 (+2.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PROCEPT BioRobotics free cash flow
In fiscal 2025, PROCEPT BioRobotics generated -$49.0 million of operating cash flow and spent $9.4 million on capital expenditures. That left free cash flow of -$58.3 million, a free-cash-flow margin of -18.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
PROCEPT BioRobotics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -95.57M | -91.41M | -105.90M | -87.15M | -59.85M | -53.02M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 6.39M | 5.23M | 3.81M | 2.84M | 3.32M | 2.86M |
| Stock-Based Compensation | 47.60M | 31.84M | 19.13M | 10.34M | 3.80M | 2.17M |
| Change in Working Capital | -6.47M | -51.50M | -35.77M | -17.66M | -4.96M | -3.83M |
| Operating Cash Flow | -48.98M | -99.21M | -108.00M | -80.38M | -57.33M | -48.34M |
| Capital Expenditures | -9.36M | -4.41M | -25.21M | -2.65M | -592.00K | -233.00K |
| Investing Cash Flow | -9.36M | -4.41M | -25.21M | -2.65M | -592.00K | -233.00K |
| Debt Issued | — | 0 | 0 | 51.20M | 0 | 24.68M |
| Debt Repaid | — | 0 | 0 | -50.00M | 0 | — |
| Financing Cash Flow | 11.19M | 180.13M | 167.79M | 3.61M | 262.12M | 106.77M |
| Net Change in Cash | -47.22M | 76.50M | 34.59M | -79.42M | 204.19M | 58.20M |
| Free Cash Flow | -58.34M | -103.62M | -133.21M | -83.03M | -57.93M | -48.58M |
This table shows 6 annual periods of PROCEPT BioRobotics's cash flow statement, from FY 2025 back to FY 2020, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PRCT's reporting calendar. What is a cash flow statement?